CNS Pharmaceuticals (CNSP) risk factors
Item 1A of every CNS Pharmaceuticals, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors33 risks6 new6 dropped8 reworded
The company faces going concern doubts and sufficient cash only into the third quarter of 2026. Management shifted its pipeline strategy toward acquiring or licensing new neurology and oncology drug candidates. Full-time employee headcount doubled from four to eight people alongside a complete executive leadership transition.
Filed Mar 31, 2026 - FY2024 10-K risk factors33 risks
The company relies heavily on the success and regulatory approval of only two drug candidates, Berubicin and TPI 287, for glioblastoma. Auditors have issued a going concern warning due to recurring operational losses and a need for substantial near-term capital. Management is extremely lean, with key executives working part-time and providing services to competing oncology entities.
Filed Mar 31, 2025